Mochizuki M, Yoo Y C, Matsuzawa K, Sato K, Saiki I, Tono-oka S, Samukawa K, Azuma I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Biol Pharm Bull. 1995 Sep;18(9):1197-202. doi: 10.1248/bpb.18.1197.
We examined the inhibitory effect of two saponin preparations from Red ginseng, 20(R)- and 20(S)-ginsenoside-Rg3, in comparison with that of ginsenoside-Rb2, on lung metastasis produced by two highly metastatic tumor cells, B16-BL6 melanoma and colon 26-M3.1 carcinoma, in syngeneic mice. In an in vitro analysis, both saponin preparations showed a significant inhibition of adhesion to fibronectin (FN) and laminin (LM) by B16-BL6 melanoma. Similarly, they significantly inhibited the invasion of B16-BL6 cells into the reconstituted basement membrane (Matrigel)/FN in a dose-dependent manner. In an experimental metastasis model using B16-BL6 melanoma, consecutive intravenous (i.v.) administrations of 100 micrograms/mouse of 20(R)- or 20(S)-ginsenoside-Rg3 1, 2, 3 and 4 d after tumor inoculation led to a significant decrease in lung metastasis. The inhibitory effect of i.v. administration of both ginseng saponins on the tumor metastasis of B16-BL6 melanoma was also recognized in a low dose of 10 micrograms/mouse. The oral administration (p.o.) of both saponins (100-1000 micrograms/mouse) induced a significant decrease in lung metastasis of B16-BL6 melanoma. Moreover, both ginseng saponins were effective in inhibiting of lung metastasis produced by colon 26-M3.1 carcinoma. When 20(R)- or 20(S)-ginsenoside-Rg3 was orally administered consecutively after tumor inoculation in a spontaneous metastasis model using B16-BL6 melanoma, both of them significantly inhibited lung metastasis. In the experiment involving neovasculization by tumor cells in vivo, both mice groups given each saponin preparation after tumor inoculation exhibited a significant decrease in the number of blood vessels oriented toward the tumor mass, with no repression of tumor size. These findings suggest that both ginseng saponins, 20(R)- and 20(S)-ginsenoside-Rg3, possess an ability to inhibit the lung metastasis of tumor cells, and the mechanism of their antimetastatic effect is related to inhibition of the adhesion and invasion of tumor cells, and also to anti-angiogenesis activity.
我们研究了红参中的两种皂苷制剂20(R)-和20(S)-人参皂苷-Rg3与人参皂苷-Rb2相比,对同基因小鼠体内由两种高转移性肿瘤细胞B16-BL6黑色素瘤细胞和结肠26-M3.1癌细胞所产生的肺转移的抑制作用。在体外分析中,两种皂苷制剂均显著抑制B16-BL6黑色素瘤细胞对纤连蛋白(FN)和层粘连蛋白(LM)的黏附。同样,它们以剂量依赖的方式显著抑制B16-BL6细胞侵袭重组基底膜(基质胶)/FN。在使用B16-BL6黑色素瘤的实验性转移模型中,在肿瘤接种后第1、2、3和4天连续静脉注射(i.v.)100微克/只小鼠的20(R)-或20(S)-人参皂苷-Rg3,导致肺转移显著减少。静脉注射两种人参皂苷对B16-BL6黑色素瘤肿瘤转移的抑制作用在低剂量10微克/只小鼠时也得到了证实。两种皂苷(100 - 1000微克/只小鼠)口服给药(p.o.)均使B16-BL6黑色素瘤的肺转移显著减少。此外,两种人参皂苷均能有效抑制结肠26-M3.1癌细胞所产生的肺转移。在使用B16-BL6黑色素瘤的自发转移模型中,肿瘤接种后连续口服20(R)-或20(S)-人参皂苷-Rg3,两者均显著抑制肺转移。在涉及肿瘤细胞体内新生血管形成的实验中,肿瘤接种后给予每种皂苷制剂的两组小鼠,朝向肿瘤块的血管数量均显著减少,且肿瘤大小未受抑制。这些发现表明,20(R)-和20(S)-人参皂苷-Rg3这两种人参皂苷均具有抑制肿瘤细胞肺转移的能力,其抗转移作用机制与抑制肿瘤细胞的黏附、侵袭以及抗血管生成活性有关。